Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Increased survival with enzalutamide in prostate cancer after chemotherapy.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators.

N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15.

2.

Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology.

Vellas B, Hampel H, Rougé-Bugat ME, Grundman M, Andrieu S, Abu-Shakra S, Bateman R, Berman R, Black R, Carrillo M, Donohue M, Mintun M, Morris J, Petersen R, Thomas RG, Suhy J, Schneider L, Seely L, Tariot P, Touchon J, Weiner M, Sampaio C, Aisen P; Task Force Participants.

J Nutr Health Aging. 2012 Apr;16(4):339-45.

PMID:
22499454
3.

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium.

Lancet. 2010 Apr 24;375(9724):1437-46. doi: 10.1016/S0140-6736(10)60172-9. Epub 2010 Apr 14.

4.

A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, Dorsey ER, Factor S, Geschwind MD, Hodgeman K, Kayson E, Noonberg S, Pourfar M, Rabinowitz K, Ravina B, Sanchez-Ramos J, Seely L, Walker F, Feigin A; Huntington Disease Study Group DIMOND Investigators.

Arch Neurol. 2010 Feb;67(2):154-60. doi: 10.1001/archneurol.2009.334. Erratum in: Arch Neurol. 2010 Apr;67(4):492. Dimebon in Subjects With Huntington Disease (DIMOND)Investigators of the Huntington Study Group [corrected to Huntington Disease Study Group DIMOND Investigators].

5.

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.

Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D; dimebon investigators.

Lancet. 2008 Jul 19;372(9634):207-15. doi: 10.1016/S0140-6736(08)61074-0.

PMID:
18640457
6.

Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery.

Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, Namini H, Hamdan AD, Roddy SP, Belkin M, Berceli SA, DeMasi RJ, Samson RH, Berman SS; PREVENT III Investigators.

J Vasc Surg. 2006 Apr;43(4):742-751; discussion 751.

7.

Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial.

Conte MS, Bandyk DF, Clowes AW, Moneta GL, Namini H, Seely L.

J Vasc Surg. 2005 Sep;42(3):456-64; discussion 464-5.

8.

A survey of attitudes about maternal serum screening for fetal chromosome abnormalities in women 35 years of age and older.

Phillips OP, Seely L, Wan JY, Wachtel SS, Shulman LP.

Fetal Diagn Ther. 1998 Nov-Dec;13(6):357-60.

PMID:
9933819
9.
10.

Glucose transport in human skeletal muscle. The in vivo response to insulin.

Bonadonna RC, Saccomani MP, Seely L, Zych KS, Ferrannini E, Cobelli C, DeFronzo RA.

Diabetes. 1993 Jan;42(1):191-8.

PMID:
8093605
11.

Patterns of mood states in pregnant women undergoing chorionic villus sampling or amniocentesis.

Tunis SL, Golbus MS, Copeland KL, Fine BA, Rosinsky BJ, Seely L.

Am J Med Genet. 1990 Oct;37(2):191-9.

PMID:
2248285
12.
13.

Transabdominal chorionic villus sampling for first-trimester prenatal diagnosis.

Elias S, Simpson JL, Shulman LP, Emerson D, Tharapel A, Seely L.

Am J Obstet Gynecol. 1989 Apr;160(4):879-84; discussion 884-6.

PMID:
2712119

Supplemental Content

Loading ...
Support Center